Astria Novitasari Nidom

Astria Novitasari Nidom

Auto-generated profile, based on publicly available information

Astria Novitasari Nidom

Doctoral Program of Medical Science, Faculty of Medicine Universitas Airlangga Surabaya Indonesia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
Arif Nur Muhammad AnsoriArif Nur Muhammad Ansori
Arif Nur Muhammad Ansori
RNReviany Vibrianita Nidom
Reviany Vibrianita Nidom
MKMuhammad K. J. Kusala
Muhammad K. J. Kusala
SISetyarina Indrasari
Setyarina Indrasari
INIrine Normalina
Irine Normalina
CNChairul A. Nidom
Chairul A. Nidom
Context: SARS-CoV-2, a member of family Coronaviridae and the causative agent of COVID-19, is a virus which is transmitted to human and other mammals. Aims: To analyze the B-cell epitope conserved region and viroinformatics-based study of the SARS-CoV-2 lineage from Indonesian B.1.1.7 isolates to invent a vaccine nominee for overcoming COVID-19. Methods: The sequences of seven Indonesian B.1.1.7 isolates, Wuhan-Hu-1 isolate, and WIV04 isolate were extracted from the GISAID EpiCoV and GenBank, NCBI. MEGA X was employed to understand the transformations of amino acid in the S protein and to develop a molecular phylogenetic tree. The IEDB was implemented to reveal the linear B-cell epitopes. In addition, PEP-FOLD3 web server was utilized to perform peptide modeling, while docking was performed using PatchDock, FireDock, and the PyMOL software. Moreover, in silico cloning was developed by using SnapGene v.3.2.1 software. Results: In this study, the changes of amino acid in all seven Indonesian B.1.1.7 isolates were uncovered. Furthermore, various peptides based on the B-cell epitope prediction, allergenicity prediction, toxicity prediction from S protein to generate a vaccine contrary to SARS-CoV-2 were identified. Furthermore, the development of in silico cloning using pET plasmid was successfully achieved. Conclusions: This study exhibits the transformations of amino acid in Indonesian B.1.1.7 isolates, and proposes four peptides (“LTPGDSSSGWTAG”, “VRQIAPGQTGKIAD”, “ILPDPSKPSKRS”, and “KNHTSPDVDLG”) from S protein as the candidate for a peptide-based vaccine. However, further advance trials such as in vitro and in vivo testing are involved for validation.

19 January 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
EPElisa D. Pratiwi
Elisa D. Pratiwi
TMTiza W. Mawaddah
Tiza W. Mawaddah
ASArif R. Sadjuri
Arif R. Sadjuri
DNDimas Tri Nugroho
Dimas Tri Nugroho
AHArip Hidayat
Arip Hidayat
CNChairul A. Nidom
Chairul A. Nidom
Background: Administering several separate childhood vaccines can reduce adherence to immunization schedules due to missed appointments and the burden of repeated injections. A hexavalent formulation targeting diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type B, and poliovirus offers a practical approach to improve compliance and streamline immunization. Methods: Toxicity testing was performed in Wistar rats and New Zealand White rabbits (60 rats and 30 rabbits). Animals were distributed into three groups: hexavalent vaccine + low-dose sIPV, hexavalent vaccine + high-dose sIPV, and control. Each animal received a 0.5 mL intramuscular injection at weeks 0, 4, 8, and 12. Clinical observations were conducted throughout the study. Serum samples were collected one day before each injection and at the endpoint, while liver tissue was collected at the endpoint. ALT and AST concentrations were analyzed using an automated analyzer, and hepatic morphology was evaluated microscopically. Results: No abnormal clinical signs related to vaccination were observed. ALT concentrations showed no significant differences (p > 0.05). AST differences (p < 0.05) were detected between the high-dose group and the control on day 27 in female rabbits and on day 83 in female rats; however, all values remained within normal physiological limits. Histopathological examination revealed no irreversible hepatic lesions, including hydropic degeneration, portal inflammation, focal necrosis, or connective tissue proliferation, and no significant differences were noted (p > 0.05). Conclusions: Repeated administration of the hexavalent vaccine candidate at low and high doses produced no toxicological effects in animal models, supporting its safety for further clinical development.

9 June 2025 in International Journal of One Health
Verified
Journal Article
Open access
RNReviany Vibrianita Nidom
Reviany Vibrianita Nidom
SISetyarina Indrasari
Setyarina Indrasari
DPDhani Prakoso
Dhani Prakoso
ANAstria N. Nidom
Astria N. Nidom
BABalqis Afifah
Balqis Afifah
Background and Aim: The Nipah virus (NiV), a highly pathogenic zoonotic paramyxovirus, presents a severe public health threat due to its high case fatality rate and potential for human-to-human transmission. Indonesia, with its extensive fruit bat habitats and dense human population, remains a crucial region for proactive NiV surveillance. This study represents the first national-scale molecular screening of NiV in Pteropus vampyrus populations across Indonesia, aimed at detecting viral circulation, identifying zoonotic hotspots, and establishing foundational data to inform public health preparedness through a One Health framework. Materials and Methods: A cross-sectional surveillance study was carried out from June 2023 to January 2024 in 13 locations across Western, Central, and Eastern Indonesia. Fruit bats were sampled in both natural roosts and anthropogenic environments such as bat markets. A total of 305 biological samples (250 swabs and 55 organ tissues) were collected and processed using quantitative reverse transcription polymerase chain reaction targeting the NiV nucleocapsid (N) gene. Positive samples (cycle threshold [Ct] ≤38) were further analyzed through partial gene sequencing and phylogenetic comparison. Results: Out of 305 bat samples, 4 (1.31%) tested positive for NiV RNA, all originating from Central and East Kalimantan. Ct values ranged from 31.0 to 34.0, indicating low viral loads. Sequence analysis of the partial N gene revealed a 95% similarity to Malaysian NiV strains, suggesting possible regional viral exchange. No positive cases were recorded in Sumatra or Java, despite extensive sampling. Ecological or host-specific resistance may explain this geographical disparity. Conclusion: This pioneering surveillance study confirms the presence of NiV in specific Indonesian bat populations and identifies Central and East Kalimantan as potential spillover zones. The findings emphasize the urgent need for a continuous, nationally coordinated surveillance program integrating wildlife, livestock, and human health sectors. Future research should prioritize longitudinal studies, ecological modeling, and genomic analyses to refine risk assessments and enhance outbreak preparedness under the One Health paradigm. Keywords: Indonesia, molecular surveillance, Nipah virus, One Health, Pteropus vampyrus, quantitative reverse transcription polymerase chain reaction, zoonosis.

15 March 2026 in Animal Models and Experimental Medicine
Verified
Journal Article
Open access
JJJonny Jonny
Jonny Jonny
SWSoetojo Wirjopranoto
Soetojo Wirjopranoto
CNChairul A. Nidom
Chairul A. Nidom
ISI Ketut Sudiana
I Ketut Sudiana
TPTerawan Agus Putranto
Terawan Agus Putranto
SKSanindita Kusumastuti
Sanindita Kusumastuti
Background: The development of nonhuman primate models that replicate human systemic lupus erythematosus (SLE) remains limited. This study aimed to develop a pristane‐induced SLE model in Macaca fascicularis and evaluate its capacity to mimic human‐like clinical and laboratory immunological alterations. Methods: An experimental, single‐arm investigation was performed using six female M. fascicularis (2–3 years old, 3–4 kg), which received a single intraperitoneal pristane injection (5 mL/kg body weight) to induce SLE and were monitored biweekly. Results: Throughout the 24‐week study period, all macaques developed hallmark SLE‐like changes without requiring a booster, including a pronounced increase in antinuclear antibody titers ( p = 0.002), with anti‐dsDNA positivity detected at the study endpoint. Significant decline was observed in hemoglobin, leukocyte, and lymphocyte count ( p < 0.05), reflecting hematologic perturbations consistent with human SLE. Physiologic deterioration, manifested as hyperthermia and weight loss, also emerged early ( p = 0.001). Biochemical assessment demonstrated mild hepatic and renal dysfunction marked by elevated serum glutamic pyruvic transaminase (SGPT) and urea concentrations ( p < 0.05). Uniform proteinuria further indicated renal involvement, although the absence of hematuria suggests a spectrum of renal injury that may be less severe than that observed in advanced human SLE and may require longer observation. Conclusion: Overall, the reproducibility of autoantibody elevation and multisystem involvement demonstrates the model's translational potential. This nonhuman primate model offers a significant framework for investigating SLE pathogenesis and assessing novel therapy approaches.

9 February 2026 in Trends in Immunotherapy
Verified
Journal Article
Open access
JJJonny Jonny
Jonny Jonny
PZPepita Zenia
Pepita Zenia
SKSanindita Kusumastuti
Sanindita Kusumastuti
SWSoetojo Wirjopranoto
Soetojo Wirjopranoto
CNChairul A. Nidom
Chairul A. Nidom
IRIrma Yurita Rosytania
Irma Yurita Rosytania
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by the production of antinuclear antibodies (ANA). While murine models are widely used for lupus research, their translational value is limited by physiological differences. Macaca fascicularis, a non-human primate, offers a closer model due to its genetic and immunological similarities to humans. Pristane (2,6,10,14-tetramethylpentadecane), a hydrocarbon oil, can induce lupus-like manifestations, including ANA production, but evidence in Macaca fascicularis remains scarce. This study assessed ANA titers following pristane induction in seven macaques, with one serving as a negative control. A single intraperitoneal dose of pristane (5 mL/kg) was administered, and ANA titers were evaluated biweekly using ELISA. ANA seropositivity (titer ≥1:80) was first detected at week 4, increasing to four macaques by week 8 and persisting at four positives in week 10. The duration of ANA positivity varied across individuals, ranging from a single week to continuous six-week responses, with one showing a biphasic pattern. The control macaque remained negative throughout. Clinical observations included alopecia, weight loss, lymphopenia, hematuria, and proteinuria in ANA-positive animals. In conclusion, pristane induced measurable autoimmunity in Macaca fascicularis, supporting its utility as a translational model for lupus research and preclinical testing of therapeutic interventions.

6 November 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
JJJonny Jonny
Jonny Jonny
CNChairul A. Nidom
Chairul A. Nidom
TPTerawan Agus Putranto
Terawan Agus Putranto
SWSoetojo Wirjopranoto
Soetojo Wirjopranoto
ISI Ketut Sudiana
I Ketut Sudiana
ALAstrid Devina Larasati
Astrid Devina Larasati
Background/Objectives: The dengue virus remains endemic in over 100 countries, transmitted by mosquito bites. Current management relies on supportive care, as no highly effective vaccine or approved antiviral exists. The CYD-TDV (Dengvaxia®) vaccine, licensed since 2015 with around 60% efficacy, raises the risk of severe dengue in seronegative children. The newer “Qdenga” vaccine offers up to 80% efficacy after a year but provides suboptimal protection against DENV-3 in seronegative individuals. Over the past two decades, virus-like particles (VLPs) have gained attention as safe, replication-incompetent vaccine platforms. This study evaluates the toxicity profile of dengue VLP-based antigens in BALB/c mice. Methods: A total of 80 BALB/C mice were randomly divided into two experimental groups: acute and chronic. Each group consisted of a treatment subgroup (10 males and 10 females) and a control subgroup (10 males and 10 females). In the acute group, the VLP was administered intramuscularly on day 1, while in the chronic group, a second VLP dose was given on day 14. The study was conducted over a 28-day period. Throughout the experiment, body temperature, body weight, mortality, and clinical signs were monitored regularly to assess the functional condition of various organs. Results: The results showed no notable alterations in mortality rates, body temperature, body weight, clinical signs, or histopathological observations of the examined organs across all groups, including in the hematological and blood biochemical parameters. Conclusions: The administration of tetravalent dengue VLP vaccine in BALB/c mice did not result in adverse effects in acute or chronic toxicity evaluations. Therefore, the VLP supports progression toward clinical evaluation, with dendritic cell activation providing additional rationale.